Alzheimer's Disease Manifests Abnormal Sphingolipid Metabolism

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2024 May 22

PMID 38774265

Authors

Baasanjav Uranbileg

Hideaki Isago

Eri Sakai

Masayuki Kubota

Yuko Saito

Makoto Kurano

Affiliations

Soon will be listed here.

Abstract

Introduction: Alzheimer's disease (AD) is associated with disturbed metabolism, prompting investigations into specific metabolic pathways that may contribute to its pathogenesis and pathology. Sphingolipids have garnered attention due to their known physiological impact on various diseases.

Methods: We conducted comprehensive profiling of sphingolipids to understand their possible role in AD. Sphingolipid levels were measured in AD brains, Cerad score B brains, and controls, as well as in induced pluripotent stem (iPS) cells (AD, PS, and control), using liquid chromatography mass spectrometry.

Results: AD brains exhibited higher levels of sphingosine (Sph), total ceramide 1-phosphate (Cer1P), and total ceramide (Cer) compared to control and Cerad-B brains. Deoxy-ceramide (Deoxy-Cer) was elevated in Cerad-B and AD brains compared to controls, with increased sphingomyelin (SM) levels exclusively in Cerad-B brains. Analysis of cell lysates revealed elevated dihydroceramide (dhSph), total Cer1P, and total SM in AD and PS cells versus controls. Multivariate analysis highlighted the relevance of Sph, Cer, Cer1P, and SM in AD pathology. Machine learning identified Sph, Cer, and Cer1P as key contributors to AD.

Discussion: Our findings suggest the potential importance of Sph, Cer1P, Cer, and SM in the context of AD pathology. This underscores the significance of sphingolipid metabolism in understanding and potentially targeting mechanisms underlying AD.

Citing Articles

Lipidome disruption in Alzheimer's disease brain: detection, pathological mechanisms, and therapeutic implications.

He S, Xu Z, Han X Mol Neurodegener. 2025; 20(1):11.

PMID: 39871348 PMC: 11773937. DOI: 10.1186/s13024-025-00803-6.

Rescue of hippocampal synaptic plasticity and memory performance by Fingolimod (FTY720) in APP/PS1 model of Alzheimer's disease is accompanied by correction in metabolism of sphingolipids, polyamines, and phospholipid saturation composition.

Kalecky K, Buitrago L, Alarcon J, Singh A, Bottiglieri T, Kaddurah-Daouk R bioRxiv. 2025; .

PMID: 39868189 PMC: 11761635. DOI: 10.1101/2025.01.17.633452.

References

Othman A, Rutti M, Ernst D, Saely C, Rein P, Drexel H . Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome?. Diabetologia. 2011; 55(2):421-31. DOI: 10.1007/s00125-011-2384-1. View

Kurano M, Jubishi D, Okamoto K, Hashimoto H, Sakai E, Morita Y . Dynamic modulations of urinary sphingolipid and glycerophospholipid levels in COVID-19 and correlations with COVID-19-associated kidney injuries. J Biomed Sci. 2022; 29(1):94. PMC: 9647768. DOI: 10.1186/s12929-022-00880-5. View

Uranbileg B, Sakai E, Kubota M, Isago H, Sumitani M, Yatomi Y . Development of an advanced liquid chromatography-tandem mass spectrometry measurement system for simultaneous sphingolipid analysis. Sci Rep. 2024; 14(1):5699. PMC: 10923881. DOI: 10.1038/s41598-024-56321-w. View

Uranbileg B, Kurano M, Kano K, Sakai E, Arita J, Hasegawa K . Sphingosine 1-phosphate lyase facilitates cancer progression through converting sphingolipids to glycerophospholipids. Clin Transl Med. 2022; 12(9):e1056. PMC: 9488530. DOI: 10.1002/ctm2.1056. View

Gassowska M, Cieslik M, Wilkaniec A, Strosznajder J . Sphingosine kinases/sphingosine-1-phosphate and death Signalling in APP-transfected cells. Neurochem Res. 2014; 39(4):645-52. PMC: 3962740. DOI: 10.1007/s11064-014-1240-3. View

Brunkhorst R, Vutukuri R, Pfeilschifter W . Fingolimod for the treatment of neurological diseases-state of play and future perspectives. Front Cell Neurosci. 2014; 8:283. PMC: 4162362. DOI: 10.3389/fncel.2014.00283. View

Murayama S, Saito Y . Neuropathological diagnostic criteria for Alzheimer's disease. Neuropathology. 2004; 24(3):254-60. DOI: 10.1111/j.1440-1789.2004.00571.x. View

Han X, Holtzman D, McKeel Jr D, Kelley J, Morris J . Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem. 2002; 82(4):809-18. DOI: 10.1046/j.1471-4159.2002.00997.x. View

Kurano M, Okamoto K, Jubishi D, Hashimoto H, Sakai E, Saigusa D . Dynamic modulations of sphingolipids and glycerophospholipids in COVID-19. Clin Transl Med. 2022; 12(10):e1069. PMC: 9549873. DOI: 10.1002/ctm2.1069. View

10.

Kim T, Tanzi R . Presenilins and Alzheimer's disease. Curr Opin Neurobiol. 1998; 7(5):683-8. DOI: 10.1016/s0959-4388(97)80089-x. View

11.

Kolesnick R, Fuks Z . Radiation and ceramide-induced apoptosis. Oncogene. 2003; 22(37):5897-906. DOI: 10.1038/sj.onc.1206702. View

12.

Chen Z, Zhong C . Oxidative stress in Alzheimer's disease. Neurosci Bull. 2014; 30(2):271-81. PMC: 5562667. DOI: 10.1007/s12264-013-1423-y. View

13.

Nakamura N, Honjo M, Yamagishi R, Kurano M, Yatomi Y, Watanabe S . Neuroprotective role of sphingolipid rheostat in excitotoxic retinal ganglion cell death. Exp Eye Res. 2021; 208:108623. DOI: 10.1016/j.exer.2021.108623. View

14.

Farooqui A, Farooqui T, Panza F, Frisardi V . Metabolic syndrome as a risk factor for neurological disorders. Cell Mol Life Sci. 2011; 69(5):741-62. PMC: 11115054. DOI: 10.1007/s00018-011-0840-1. View

15.

Bertea M, Rutti M, Othman A, Marti-Jaun J, Hersberger M, von Eckardstein A . Deoxysphingoid bases as plasma markers in diabetes mellitus. Lipids Health Dis. 2010; 9:84. PMC: 2931514. DOI: 10.1186/1476-511X-9-84. View

16.

Couttas T, Kain N, Daniels B, Lim X, Shepherd C, Kril J . Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. Acta Neuropathol Commun. 2014; 2:9. PMC: 3906863. DOI: 10.1186/2051-5960-2-9. View

17.

Singh D . Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer's disease. J Neuroinflammation. 2022; 19(1):206. PMC: 9382837. DOI: 10.1186/s12974-022-02565-0. View

18.

Strang K, Golde T, Giasson B . MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab Invest. 2019; 99(7):912-928. PMC: 7289372. DOI: 10.1038/s41374-019-0197-x. View

19.

Ghasemi R, Dargahi L, Ahmadiani A . Integrated sphingosine-1 phosphate signaling in the central nervous system: From physiological equilibrium to pathological damage. Pharmacol Res. 2016; 104:156-64. DOI: 10.1016/j.phrs.2015.11.006. View

20.

Kosicek M, Zetterberg H, Andreasen N, Peter-Katalinic J, Hecimovic S . Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer's disease. Neurosci Lett. 2012; 516(2):302-5. DOI: 10.1016/j.neulet.2012.04.019. View